Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

This Study Will Evaluate if the Field Force Pulsed Field Ablation System is Safe and Effective for Treating Sustained Monomorphic Ventricular Tachycardia, a Potentially Serious Fast Heart Rhythm of the Heart. The Treatment Uses Short Pulses of Energy to Target and Destroy the Heart Tissue Causing VT

14 settembre 2026 aggiornato da: Field Medical

Pivotal Study to Evaluate Catheter Ablation in Patients With Scar-Related Monomorphic Sustained VT in the Ventricular Ectopy and Reduction in Tachycardia Ablation Studies Program (VERITAS SCAR VT)

The VERITAS VT Study is a prospective, multicenter, international, single-arm clinical investigation designed to evaluate the safety and effectiveness of the FieldForce™ Pulsed Field Ablation System for the treatment of sustained monomorphic ventricular tachycardia (VT). Eligible patients undergoing catheter ablation for VT will receive treatment with the investigational pulsed field ablation system according to the study protocol.

The study will assess acute and chronic outcomes including major adverse events, freedom from recurrent ventricular tachycardia, need for antiarrhythmic drug escalation, repeat ablation procedures, and other clinically relevant outcomes through 180 days following the index ablation procedure.

Panoramica dello studio

Stato

Non ancora reclutamento

Condizioni

Intervento / Trattamento

Descrizione dettagliata

Ventricular tachycardia remains a significant source of morbidity and mortality among patients with structural heart disease. Although catheter ablation is an established therapeutic option, long-term recurrence rates remain substantial and procedural challenges continue to exist.

The VERITAS VT Study is a prospective, multicenter, single-arm clinical investigation evaluating the safety and effectiveness of the Field Force Pulsed Field Ablation System in subjects with sustained monomorphic ventricular tachycardia. Eligible participants will undergo mapping and ablation using the Field Force Pulsed Field Ablation System during the index procedure. Subjects will be followed for 180 days after the index procedure to assess safety and effectiveness outcomes.

The primary safety objective is to evaluate the incidence of device- and procedure-related major adverse events. The primary effectiveness objective is to evaluate freedom from recurrence of sustained monomorphic ventricular tachycardia through 180 days following the index ablation procedure

Tipo di studio

Interventistico

Iscrizione (Stimato)

180

Fase

  • Non applicabile

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

  • Adulto
  • Adulto più anziano

Accetta volontari sani

No

Descrizione

Inclusion Criteria:

  1. Signed patient informed consent form (ICF).
  2. Female and male patients aged ≥ 18 and ≤ 85 years.
  3. Implantable Cardioverter-Defibrillator (ICD) implanted ≥ 180 days prior to enrollment.
  4. Clinically Indicated for ventricular tachycardia (VT) ablation by 2019 guidelines:

    • At least one (1) episode of VT, defined as continuous VT lasting > 30 seconds or requiring termination due to hemodynamic compromise, detected by an implanted ICD ≤ 180 days prior to enrollment and
    • Refractory to, contraindicated or intolerant of at least one (1) Class I or III Antiarrhythmic Drug (AAD)
  5. Sustained scar-related monomorphic ventricular tachycardia (MMVT):

    • Objective evidence of ventricular scar confirmed by imaging (magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), intracardiac echocardiography/ transesophageal echocardiogram (ICE/TEE) and/or electro anatomical mapping (EAM)) Or
    • Prior myocardial infarction (MI)
  6. Left ventricular ejection fraction (LVEF) ≥ 20% confirmed by echocardiography or comparable imaging techniques within 180 days prior to enrollment or during baseline evaluation.

Exclusion Criteria:

Subjects will be excluded if ANY of the following apply:

  1. VT secondary to reversible causes (e.g. electrolyte abnormalities, drug or alcohol-induced arrhythmia or non-cardiac cause).
  2. VT ablation within 14 days prior to enrollment.
  3. Greater than three (3) VT ablations within one (1) year prior to enrollment.
  4. Ventricular fibrillation (VF), polymorphic VT or Torsades de Pointes (TdP) as primary clinical arrhythmia.
  5. Bundle branch reentry (BBR), Idiopathic, Para-Hisian or Fascicular VT.
  6. For non-ischemic cardiomyopathy (NICM) if the following apply:

    • Active (within 120 days) inflammatory process (e.g. myocarditis)
    • Sarcoidosis
    • Hypertrophic cardiomyopathy (HCM)
    • Laminopathy (LMNA-related cardiomyopathy)
    • Brugada syndrome (BrS)
    • Amyloidosis
  7. Acute myocardial infarction ≤ 90 days prior to enrollment.
  8. Recent cardiac intervention ≤ 90 days prior to enrollment including but not limited to Percutaneous Coronary Intervention (PCI) or Coronary Artery Bypass Graft (CABG), lead revision or upgrade, etc.
  9. Implanted with a ventricular assist device (VAD).
  10. Severe mitral or aortic regurgitation or stenosis evaluated by echo or comparable technique.
  11. Presence of an aortic or mitral mechanical valve.
  12. New York Heart Association (NYHA) Class IV heart failure.
  13. Uncontrolled abnormal bleeding and/or clotting disorder.
  14. Contraindication to systemic or oral anticoagulation.
  15. Presence of active intracardiac thrombus detected by imaging (pre-procedural via transesophageal echocardiogram (TEE) or transthoracic echocardiogram (TTE), CT, MRI, or intra-procedural via intracardiac echocardiography (ICE).
  16. Ineligible for ablation according to physician judgement (including but not limited to hemodynamically unstable, prior interatrial patch, Amplatzer, etc.).
  17. Serious or untreated medical conditions that would prevent participation in the study interfere with assessment or therapy, or confound data or its interpretation, including but not limited to solid organ or hematologic transplant, or currently being evaluated for an organ transplant.
  18. Severe lung disease, pulmonary hypertension, or any lung disease involving abnormal blood gases or significant dyspnea at the time of enrollment.
  19. Body Mass Index ≥ 40.
  20. Chronic renal insufficiency of estimated glomerular filtration rate (eGFR) < 30 mL/min/1.73 m2.
  21. Active malignancy.
  22. Active systemic infection.
  23. Life expectancy is less than one year.
  24. Prohibitively distorted cardiac anatomy due to congenital heart disease.
  25. Participation in another investigational study that may interfere with the procedure outcomes for this study unless pre-approved by sponsor.
  26. Unable to understand the nature of this study or is unwilling or unable to attend all the study visits.
  27. Pregnancy or planned pregnancy, lactating or any women of childbearing potential who is not on a reliable form of birth control.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: N / A
  • Modello interventistico: Assegnazione di gruppo singolo
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: Field Force Pulsed Fiel Ablation
Participants will undergo ventricular tachycardia ablation using the Field Force Pulsed Field Ablation System during the index procedure.
The Field Force Pulsed Field Ablation System is an investigational device that delivers non-thermal pulsed electric field energy through a catheter-based platform to ablate targeted cardiac tissue. The system is intended for use during catheter ablation procedures in patients with sustained monomorphic ventricular tachycardia (VT) to treat tissue involved in the initiation and maintenance of the arrhythmia.

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Primary Safety Endpoint - Freedom from casual or probable device or procedure related Major Adverse Events (MAEs) that occur within 7 days following the ablation procedure. (Or within 90 days for esophageal events (fistula/perforation)
Lasso di tempo: As applicable within 7 days or 90 days after the index ablation procedure
A pre-defined list of device - or procedure-related MAEs, as adjudicated by the Clinical Events Committee (CEC), occurring within 7 days after the index ablation procedure (or within 3 months after the index ablation procedure for any esophago-pericardial fistula/esophageal perforation) will be considered a primary safety event
As applicable within 7 days or 90 days after the index ablation procedure
Primary Effectiveness: Freedom from recurrence of sustained monomorphic VT
Lasso di tempo: Through 6 months most the index ablation procedure
Freedom from recurrence of sustained monomorphic VT (MMVT) in the absence of new or increased dose of Class I or III antiarrhythmic drugs (AAD) for any ventricular arrhythmia through 6 months after the index ablation procedure
Through 6 months most the index ablation procedure

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Secondary Effectiveness Endpoint: Percentage of patients with reduced ventricular tachycardia burden
Lasso di tempo: 6 months post index procedure
Percentage of patients with reduced ventricular tachycardia burden
6 months post index procedure

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Collaboratori

Investigatori

  • Investigatore principale: Vivek Reddy, MD, Mount Sinai Hospital

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Stimato)

1 dicembre 2026

Completamento primario (Stimato)

1 agosto 2027

Completamento dello studio (Stimato)

1 febbraio 2028

Date di iscrizione allo studio

Primo inviato

26 agosto 2026

Primo inviato che soddisfa i criteri di controllo qualità

26 agosto 2026

Primo Inserito (Effettivo)

31 agosto 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

16 settembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

14 settembre 2026

Ultimo verificato

1 settembre 2026

Maggiori informazioni

Termini relativi a questo studio

Altri numeri di identificazione dello studio

  • CLN-00011

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

NO

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

prodotto fabbricato ed esportato dagli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .